Miriam A Bredella1, Anu V Gerweck2, Lauren A Barber3, Anne Breggia4, Clifford J Rosen4, Martin Torriani3, Karen K Miller2. 1. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: mbredella@partners.org. 2. Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Bulfinch 457B, 55 Fruit Street, Boston, MA, USA. 3. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA 02114, USA. 4. Maine Medical Center Research Institute, Scarborough, ME 04074, USA.
Abstract
PURPOSE: Abdominal adiposity is associated with low BMD and decreased growth hormone (GH) secretion, an important regulator of bone homeostasis. The purpose of our study was to determine the effects of a short course of GH on markers of bone turnover and bone marrow fat in premenopausal women with abdominal adiposity. MATERIALS AND METHODS: In a 6-month, randomized, double-blind, placebo-controlled trial we studied 79 abdominally obese premenopausal women (21-45 y) who underwentdaily sc injections of GH vs. placebo. Main outcome measures were body composition by DXA and CT, bone marrow fat by proton MR spectroscopy, P1NP, CTX, 25(OH)D, hsCRP, undercarboxylated osteocalcin (ucOC), preadipocyte factor 1 (Pref 1), apolipoprotein B (ApoB), and IGF-1. RESULTS:GH increased IGF-1, P1NP, 25(OH)D, ucOC, bone marrow fat and lean mass, and decreased abdominal fat, hsCRP, and ApoB compared with placebo (p<0.05). There was a trend toward an increase in CTX and Pref-1. Among all participants, a 6-month increase in IGF-1 correlated with 6-month increase in P1NP (p=0.0005), suggesting that subjects with the greatest increases in IGF-1 experienced the greatest increases in bone formation. A six-month decrease in abdominal fat, hsCRP, and ApoB inversely predicted 6-month change in P1NP, and 6-month increase in lean mass and 25(OH)D positively predicted 6-month change in P1NP (p≤0.05), suggesting that subjects with greatest decreases in abdominal fat, inflammation and ApoB, and the greatest increases in lean mass and 25(OH)D experienced the greatest increases in bone formation. A six-month increase in bone marrow fat correlated with 6-month increase in P1NP (trend), suggesting that subjects with the greatest increases in bone formation experienced the greatest increases in bone marrow fat. Forward stepwise regression analysis indicated that increase in lean mass and decrease in abdominal fat were positive predictors of P1NP. When IGF-1 was added to the model, it became the only predictor of P1NP. CONCLUSION:GH replacement in abdominally obese premenopausal women for 6 months increased bone turnover and bone marrow fat. Reductions in abdominal fat, and inflammation, and increases in IGF-1, lean mass and vitamin D were associated with increased bone formation. The increase in bone marrow fat may reflect changes in energy demand from increased bone turnover.
RCT Entities:
PURPOSE: Abdominal adiposity is associated with low BMD and decreased growth hormone (GH) secretion, an important regulator of bone homeostasis. The purpose of our study was to determine the effects of a short course of GH on markers of bone turnover and bone marrow fat in premenopausal women with abdominal adiposity. MATERIALS AND METHODS: In a 6-month, randomized, double-blind, placebo-controlled trial we studied 79 abdominally obese premenopausal women (21-45 y) who underwent daily sc injections of GH vs. placebo. Main outcome measures were body composition by DXA and CT, bone marrow fat by proton MR spectroscopy, P1NP, CTX, 25(OH)D, hsCRP, undercarboxylated osteocalcin (ucOC), preadipocyte factor 1 (Pref 1), apolipoprotein B (ApoB), and IGF-1. RESULTS:GH increased IGF-1, P1NP, 25(OH)D, ucOC, bone marrow fat and lean mass, and decreased abdominal fat, hsCRP, and ApoB compared with placebo (p<0.05). There was a trend toward an increase in CTX and Pref-1. Among all participants, a 6-month increase in IGF-1 correlated with 6-month increase in P1NP (p=0.0005), suggesting that subjects with the greatest increases in IGF-1 experienced the greatest increases in bone formation. A six-month decrease in abdominal fat, hsCRP, and ApoB inversely predicted 6-month change in P1NP, and 6-month increase in lean mass and 25(OH)D positively predicted 6-month change in P1NP (p≤0.05), suggesting that subjects with greatest decreases in abdominal fat, inflammation and ApoB, and the greatest increases in lean mass and 25(OH)D experienced the greatest increases in bone formation. A six-month increase in bone marrow fat correlated with 6-month increase in P1NP (trend), suggesting that subjects with the greatest increases in bone formation experienced the greatest increases in bone marrow fat. Forward stepwise regression analysis indicated that increase in lean mass and decrease in abdominal fat were positive predictors of P1NP. When IGF-1 was added to the model, it became the only predictor of P1NP. CONCLUSION:GH replacement in abdominally obese premenopausal women for 6 months increased bone turnover and bone marrow fat. Reductions in abdominal fat, and inflammation, and increases in IGF-1, lean mass and vitamin D were associated with increased bone formation. The increase in bone marrow fat may reflect changes in energy demand from increased bone turnover.
Authors: T B Hansen; K Brixen; N Vahl; J O Jørgensen; J S Christiansen; L Mosekilde; C Hagen Journal: J Clin Endocrinol Metab Date: 1996-09 Impact factor: 5.958
Authors: F Parhami; A D Morrow; J Balucan; N Leitinger; A D Watson; Y Tintut; J A Berliner; L L Demer Journal: Arterioscler Thromb Vasc Biol Date: 1997-04 Impact factor: 8.311
Authors: H B Baum; B M Biller; J S Finkelstein; K B Cannistraro; D S Oppenhein; D A Schoenfeld; T H Michel; H Wittink; A Klibanski Journal: Ann Intern Med Date: 1996-12-01 Impact factor: 25.391
Authors: J O Jørgensen; N Vahl; T B Hansen; C Skjaerbaek; S Fisker; H Orskov; C Hagen; J S Christiansen Journal: Clin Endocrinol (Oxf) Date: 1998-04 Impact factor: 3.478
Authors: Basem M Abdallah; Ming Ding; Charlotte H Jensen; Nicholas Ditzel; Allan Flyvbjerg; Thomas G Jensen; Frederik Dagnaes-Hansen; Jürg A Gasser; Moustapha Kassem Journal: Endocrinology Date: 2007-04-19 Impact factor: 4.736
Authors: Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Martin Torriani; Karen K Miller; Miriam A Bredella Journal: Skeletal Radiol Date: 2016-03-16 Impact factor: 2.199
Authors: S V Lim; M Marenzana; M Hopkinson; E O List; J J Kopchick; M Pereira; B Javaheri; J P Roux; P Chavassieux; M Korbonits; C Chenu Journal: Endocrinology Date: 2015-02-03 Impact factor: 4.736
Authors: Katherine N Bachmann; Alexander G Bruno; Miriam A Bredella; Melanie Schorr; Elizabeth A Lawson; Corey M Gill; Vibha Singhal; Erinne Meenaghan; Anu V Gerweck; Kamryn T Eddy; Seda Ebrahimi; Stuart L Koman; James M Greenblatt; Robert J Keane; Thomas Weigel; Esther Dechant; Madhusmita Misra; Anne Klibanski; Mary L Bouxsein; Karen K Miller Journal: J Bone Miner Res Date: 2015-09-17 Impact factor: 6.741
Authors: Josefine Tratwal; Rossella Labella; Nathalie Bravenboer; Greet Kerckhofs; Eleni Douni; Erica L Scheller; Sammy Badr; Dimitrios C Karampinos; Sarah Beck-Cormier; Biagio Palmisano; Antonella Poloni; Maria J Moreno-Aliaga; Jackie Fretz; Matthew S Rodeheffer; Parastoo Boroumand; Clifford J Rosen; Mark C Horowitz; Bram C J van der Eerden; Annegreet G Veldhuis-Vlug; Olaia Naveiras Journal: Front Endocrinol (Lausanne) Date: 2020-02-28 Impact factor: 5.555